Skip to main content
. 2020 Sep 28;130(11):5738–5755. doi: 10.1172/JCI138540

Figure 5. Treatment of C57BL/6 normal mouse primary pituitary cultures with forskolin and rolipram.

Figure 5

(A) GH, (B) ACTH, (C) PRL, and (D) FSH concentrations in supernatant after treatment with vehicle (V), 10 μM forskolin (FSK), cotreatment with 10 μM forskolin and 1 μM rolipram (FSK + RLP), or 1 μM rolipram alone, normalized to WST1. n = 6 per treatment group. (E) Quantitative presentation of Western blot results depicting the change in γH2AX levels normalized to total H2AX after 16 hours of treatment as above. Results were derived from 3 separate wells. Band intensities were calculated by ImageJ. The full panel is shown in Supplemental Figure 7B. (F) Results of the comet assay depicting Olive tail moment measurement 16 hours after treatment as above. Results were pooled from 2 experiments. The number of cells analyzed by a blinded observer is indicated. Results are presented as the mean ± SEM (vehicle, 20.8 ± 1.0; forskolin, 38.2 ± 1.4; forskolin plus rolipram, 42.7 ± 1.5; rolipram, 28.1 ± 1.1). *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001 versus vehicle; #P ≤ 0.05 versus forskolin, by 2-tailed, unpaired t test with Bonferroni’s correction. The experiments were performed at least twice.